ClinicalTrials.gg
CompletedNCT02846532UNIVERSEUpdated Mar 30, 2025Results posted

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

A Phase 3 interventional study of Rivaroxaban and Acetylsalicylic Acid in Thrombosis, sponsored by Janssen Research & Development, LLC. Completed at 42 sites in 10 countries. Open to participants aged 2 Years to 8 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
2 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing rivaroxaban in Thrombosis — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thrombosis.

Enrollment
13th of 30
112 · median 84
Started
2016
with 2 others
Phase 3
11 of 30
1 open now
Registered
17th of 30
by date
Lead sponsor
2 of 30
Janssen Research & Development, LLC

Among the 30 studies testing rivaroxaban in Thrombosis, this one is the 13th largest by enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 17th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

4 of the 30 studies testing rivaroxaban in Thrombosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 2 Years to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing rivaroxaban in Thrombosis, or all of them as a file.
02

Study summary

The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment (Part A) and to evaluate the safety and efficacy of rivaroxaban, administered twice daily (exposure matched to rivaroxaban 10 milligram [mg] once daily in adults) compared to acetylsalicylic acid (ASA), given once daily (approximately 5 milligram per kilogram [mg/kg]) for thromboprophylaxis in pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment.

Read the detailed description

Part A: This part includes a 12-day Initial PK, PD, and Safety Assessment Period. Participants in Part A will not participate in Part B. Randomization in Part B of this study will begin once the cumulative data from the Initial PK, PD, and Safety Assessment Period in Part A are deemed acceptable by the Independent Data Monitoring Committee. Part A of the study will consist of an up to 21-day Screening Period, a 12-day Initial PK, PD, and Safety Assessment Period, a 12-month Open-Label Treatment Period, and a 30-day Follow-Up phone contact. Part B: Participants will be randomly assigned to two treatment groups and randomization ratio will be 2:1 for rivaroxaban and ASA. ASA will be used as control. There will be an up to a 21-day Screening Period, a 12 month Open-Label Treatment Period and a 30-day Follow-Up phone contact.

03

Conditions studied

  • Thrombosis

Keywords

  • Thromboembolism
  • Fontan Procedure
  • Children
04

Who can participate

Ages eligible
2 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be considered to be clinically stable by the investigator and able to tolerate oral or enteral administration of a suspension formulation and oral/enteral feedings
  • Satisfactory initial post-Fontan transthoracic echocardiographic Screening as defined in the Post-Fontan Echocardiographic Examination Research Protocol
  • Parent/legally acceptable representative must sign an form (ICF) and child assent will also be provided, if applicable, according to local requirements

Exclusion criteria

Exclusion Criteria:

  • Evidence of thrombosis, including those that are asymptomatic confirmed by post-Fontan procedure transthoracic echocardiogram, or other imaging techniques, during the Screening period of the study
  • History of gastrointestinal disease or surgery associated with impaired absorption
  • History of or signs/symptoms suggestive of protein-losing enteropathy
  • Active bleeding or high risk for bleeding contraindicating antiplatelet or anticoagulant therapy, including a history of intracranial bleeding
  • count less than (\<)50*10\^9/Liters (L) at Screening
  • Estimated (eGFR) \<30 milliliters per minute per 1.73 meter square (mL/min/1.73m\^2)
  • Known clinically significant liver disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Drug: Rivaroxaban

  • Experimental
    Acetylsalicylic Acid

    Drug: Acetylsalicylic Acid

Interventions

  • Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.

  • Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic)

    Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis.

    Time frame: Up to 12 months

  2. Plasma Concentration of Rivaroxaban at Day 1 (0.5-1.5 Hours Postdose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 0.5-1.5 hours postdose

  3. Plasma Concentration of Rivaroxaban at Day 1 (1.5-4 Hours Postdose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 1.5-4 hours postdose

  4. Plasma Concentration of Rivaroxaban at Day 4 (Up to 3 Hours Predose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: Up to 3 hours predose

  5. Plasma Concentration of Rivaroxaban at Day 4 (0.5-1.5 Hours Postdose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 0.5-1.5 hours postdose

  6. Plasma Concentration of Rivaroxaban at Day 4 (1.5-4 Hours Postdose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 1.5-4 hours postdose

  7. Plasma Concentration of Rivaroxaban at Day 4 (6-8 Hours Postdose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 6-8 hours postdose

  8. Plasma Concentration of Rivaroxaban at Month 3 (Up to 3 Hours Predose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: Up to 3 hours predose

  9. Plasma Concentration of Rivaroxaban at Month 3 (0.5-1.5 Hours Postdose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 0.5-1.5 hours postdose

  10. Plasma Concentration of Rivaroxaban at Month 3 (2.5-4 Hours Postdose)

    Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 2.5-4 hours postdose

  11. Percentage of Participants With Bleeding Events

    Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding.

    Time frame: Up to 12 months

  12. Absolute Prothrombin Time (PT) at Day 1 (0.5-1.5 Hours Postdose)

    Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 0.5-1.5 hours postdose

  13. Absolute PT at Day 1 (1.5-4 Hours Postdose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 1.5-4 hours postdose

  14. Absolute PT at Day 4 (Up to 3 Hours Predose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.

    Time frame: Day 4: Up to 3 hours predose

  15. Absolute PT at Day 4 (0.5-1.5 Hours Postdose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 0.5-1.5 hours postdose

  16. Absolute PT at Day 4 (1.5-4 Hours Postdose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 1.5-4 hours postdose

  17. Absolute PT at Day 4 (6-8 Hours Postdose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 6-8 hours postdose

  18. Absolute PT at Month 3 (Up to 3 Hours Predose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: Up to 3 hours predose

  19. Absolute PT at Month 3 (0.5-1.5 Hours Postdose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 0.5-1.5 hours postdose

  20. Absolute PT at Month 3 (2.5-4 Hours Postdose)

    Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 2.5-4 hours postdose

  21. Activated Partial Thromboplastin Time (aPTT) at Day 1 (0.5-1.5 Hours Postdose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 0.5-1.5 hours postdose

  22. aPTT at Day 1 (1.5-4 Hours Postdose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 1.5-4 hours postdose

  23. aPTT at Day 4 (Up to 3 Hours Predose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: Up to 3 hours predose

  24. aPTT at Day 4 (0.5-1.5 Hours Postdose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.

    Time frame: Day 4: 0.5-1.5 hours postdose

  25. aPTT at Day 4 (1.5-4 Hours Postdose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here.

    Time frame: Day 4: 1.5-4 hours postdose

  26. aPTT at Day 4 (6-8 Hours Postdose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 6-8 hours postdose

  27. aPTT at Month 3 (Up to 3 Hours Predose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: Up to 3 hours predose

  28. aPTT at Month 3 (0.5-1.5 Hours Postdose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 0.5-1.5 hours postdose

  29. aPTT at Month 3 (2.5-4 Hours Postdose)

    aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 2.5-4 hours postdose

  30. Anti-FXa at Day 1 (0.5-1.5 Hours Postdose)

    Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 0.5-1.5 hours postdose

  31. Anti-FXa at Day 1 (1.5-4 Hours Postdose)

    Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 1: 1.5-4 hours postdose

  32. Anti-FXa at Day 4 (6-8 Hours Postdose)

    Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Day 4: 6-8 hours postdose

  33. Anti-FXa at Month 3 (Up to 3 Hours Predose)

    Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: Up to 3 hours predose

  34. Anti-FXa at Month 3 (0.5-1.5 Hours Postdose)

    Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 0.5-1.5 hours postdose

  35. Anti-FXa at Month 3 (2.5-4 Hours Postdose)

    Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

    Time frame: Month 3: 2.5-4 hours postdose

Secondary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 12 months

07

Results

Posted Mar 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneRivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)
Started126634
Completed116333
Not completed131
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject120

Outcome measures

PrimaryPercentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic)

Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis.

Time frame:
Up to 12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic)
percentage of participantsRivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)
Any thrombotic event8.31.68.8
Ischemic stroke002.9
Pulmonary embolism01.60
Venous thrombosis8.305.9
Arterial/intracardiac thrombosis000
Other thrombosis000
PrimaryPlasma Concentration of Rivaroxaban at Day 1 (0.5-1.5 Hours Postdose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 0.5-1.5 hours postdose
Reported as:
Mean · micrograms per liter (mcg/L)
Plasma Concentration of Rivaroxaban at Day 1 (0.5-1.5 Hours Postdose)
micrograms per liter (mcg/L)Rivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Day 1 (0.5-1.5 Hours Postdose)46.69 ± 39.492.86 ± 72.6
PrimaryPlasma Concentration of Rivaroxaban at Day 1 (1.5-4 Hours Postdose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 1.5-4 hours postdose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Day 1 (1.5-4 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Day 1 (1.5-4 Hours Postdose)86.62 ± 43.1103.61 ± 62.6
PrimaryPlasma Concentration of Rivaroxaban at Day 4 (Up to 3 Hours Predose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: Up to 3 hours predose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Day 4 (Up to 3 Hours Predose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Day 4 (Up to 3 Hours Predose)36.58 ± 37.4—
PrimaryPlasma Concentration of Rivaroxaban at Day 4 (0.5-1.5 Hours Postdose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 0.5-1.5 hours postdose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Day 4 (0.5-1.5 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Day 4 (0.5-1.5 Hours Postdose)107.58 ± 54.2—
PrimaryPlasma Concentration of Rivaroxaban at Day 4 (1.5-4 Hours Postdose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 1.5-4 hours postdose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Day 4 (1.5-4 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Day 4 (1.5-4 Hours Postdose)147.18 ± 116—
PrimaryPlasma Concentration of Rivaroxaban at Day 4 (6-8 Hours Postdose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 6-8 hours postdose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Day 4 (6-8 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Day 4 (6-8 Hours Postdose)66.81 ± 64.6—
PrimaryPlasma Concentration of Rivaroxaban at Month 3 (Up to 3 Hours Predose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: Up to 3 hours predose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Month 3 (Up to 3 Hours Predose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Month 3 (Up to 3 Hours Predose)38.23 ± 25.729.41 ± 25.5
PrimaryPlasma Concentration of Rivaroxaban at Month 3 (0.5-1.5 Hours Postdose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 0.5-1.5 hours postdose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Month 3 (0.5-1.5 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Month 3 (0.5-1.5 Hours Postdose)86.25 ± 32.094.12 ± 82.2
PrimaryPlasma Concentration of Rivaroxaban at Month 3 (2.5-4 Hours Postdose)

Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 2.5-4 hours postdose
Reported as:
Mean · mcg/L
Plasma Concentration of Rivaroxaban at Month 3 (2.5-4 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Plasma Concentration of Rivaroxaban at Month 3 (2.5-4 Hours Postdose)96.67 ± 58.4102.99 ± 56.0
PrimaryPercentage of Participants With Bleeding Events

Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding.

Time frame:
Up to 12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Bleeding Events
percentage of participantsRivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)
Any bleeding event33.335.941.2
Major Bleeding01.60
Clinically relevant non-major bleeding8.36.38.8
Trivial bleeding25.032.835.3
PrimaryAbsolute Prothrombin Time (PT) at Day 1 (0.5-1.5 Hours Postdose)

Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 0.5-1.5 hours postdose
Reported as:
Mean · seconds
Absolute Prothrombin Time (PT) at Day 1 (0.5-1.5 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute Prothrombin Time (PT) at Day 1 (0.5-1.5 Hours Postdose)15.46 ± 1.9018.02 ± 2.58
PrimaryAbsolute PT at Day 1 (1.5-4 Hours Postdose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 1.5-4 hours postdose
Reported as:
Mean · seconds
Absolute PT at Day 1 (1.5-4 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Day 1 (1.5-4 Hours Postdose)16.58 ± 1.8418.76 ± 2.25
PrimaryAbsolute PT at Day 4 (Up to 3 Hours Predose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.

Time frame:
Day 4: Up to 3 hours predose
Reported as:
Mean · seconds
Absolute PT at Day 4 (Up to 3 Hours Predose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Day 4 (Up to 3 Hours Predose)15.21 ± 1.54—
PrimaryAbsolute PT at Day 4 (0.5-1.5 Hours Postdose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 0.5-1.5 hours postdose
Reported as:
Mean · seconds
Absolute PT at Day 4 (0.5-1.5 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Day 4 (0.5-1.5 Hours Postdose)17.95 ± 2.10—
PrimaryAbsolute PT at Day 4 (1.5-4 Hours Postdose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 1.5-4 hours postdose
Reported as:
Mean · seconds
Absolute PT at Day 4 (1.5-4 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Day 4 (1.5-4 Hours Postdose)18.73 ± 3.30—
PrimaryAbsolute PT at Day 4 (6-8 Hours Postdose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 6-8 hours postdose
Reported as:
Mean · seconds
Absolute PT at Day 4 (6-8 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Day 4 (6-8 Hours Postdose)16.13 ± 2.13—
PrimaryAbsolute PT at Month 3 (Up to 3 Hours Predose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: Up to 3 hours predose
Reported as:
Mean · seconds
Absolute PT at Month 3 (Up to 3 Hours Predose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Month 3 (Up to 3 Hours Predose)17.59 ± 2.6516.45 ± 2.27
PrimaryAbsolute PT at Month 3 (0.5-1.5 Hours Postdose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 0.5-1.5 hours postdose
Reported as:
Mean · seconds
Absolute PT at Month 3 (0.5-1.5 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Month 3 (0.5-1.5 Hours Postdose)20.13 ± 3.5518.89 ± 3.69
PrimaryAbsolute PT at Month 3 (2.5-4 Hours Postdose)

Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 2.5-4 hours postdose
Reported as:
Mean · seconds
Absolute PT at Month 3 (2.5-4 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Absolute PT at Month 3 (2.5-4 Hours Postdose)19.14 ± 2.6119.69 ± 2.81
PrimaryActivated Partial Thromboplastin Time (aPTT) at Day 1 (0.5-1.5 Hours Postdose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 0.5-1.5 hours postdose
Reported as:
Mean · seconds
Activated Partial Thromboplastin Time (aPTT) at Day 1 (0.5-1.5 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
Activated Partial Thromboplastin Time (aPTT) at Day 1 (0.5-1.5 Hours Postdose)31.4 ± 4.6830.69 ± 8.23
PrimaryaPTT at Day 1 (1.5-4 Hours Postdose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 1.5-4 hours postdose
Reported as:
Mean · seconds
aPTT at Day 1 (1.5-4 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Day 1 (1.5-4 Hours Postdose)32.83 ± 3.7930.25 ± 3.80
PrimaryaPTT at Day 4 (Up to 3 Hours Predose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: Up to 3 hours predose
Reported as:
Mean · seconds
aPTT at Day 4 (Up to 3 Hours Predose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Day 4 (Up to 3 Hours Predose)33.08 ± 5.68—
PrimaryaPTT at Day 4 (0.5-1.5 Hours Postdose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.

Time frame:
Day 4: 0.5-1.5 hours postdose
Reported as:
Mean · seconds
aPTT at Day 4 (0.5-1.5 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Day 4 (0.5-1.5 Hours Postdose)36.17 ± 6.99—
PrimaryaPTT at Day 4 (1.5-4 Hours Postdose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here.

Time frame:
Day 4: 1.5-4 hours postdose
Reported as:
Mean · seconds
aPTT at Day 4 (1.5-4 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Day 4 (1.5-4 Hours Postdose)37.58 ± 8.45—
PrimaryaPTT at Day 4 (6-8 Hours Postdose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 6-8 hours postdose
Reported as:
Mean · seconds
aPTT at Day 4 (6-8 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Day 4 (6-8 Hours Postdose)32.83 ± 5.94—
PrimaryaPTT at Month 3 (Up to 3 Hours Predose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: Up to 3 hours predose
Reported as:
Mean · seconds
aPTT at Month 3 (Up to 3 Hours Predose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Month 3 (Up to 3 Hours Predose)25.36 ± 3.7628.70 ± 3.76
PrimaryaPTT at Month 3 (0.5-1.5 Hours Postdose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 0.5-1.5 hours postdose
Reported as:
Mean · seconds
aPTT at Month 3 (0.5-1.5 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Month 3 (0.5-1.5 Hours Postdose)26.60 ± 2.5531.15 ± 4.17
PrimaryaPTT at Month 3 (2.5-4 Hours Postdose)

aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 2.5-4 hours postdose
Reported as:
Mean · seconds
aPTT at Month 3 (2.5-4 Hours Postdose)
secondsRivaroxaban (Part A)Rivaroxaban (Part B)
aPTT at Month 3 (2.5-4 Hours Postdose)26.74 ± 1.7931.67 ± 3.58
PrimaryAnti-FXa at Day 1 (0.5-1.5 Hours Postdose)

Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 0.5-1.5 hours postdose
Reported as:
Mean · mcg/L
Anti-FXa at Day 1 (0.5-1.5 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Anti-FXa at Day 1 (0.5-1.5 Hours Postdose)66.93 ± 23.999.46 ± 60.6
PrimaryAnti-FXa at Day 1 (1.5-4 Hours Postdose)

Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 1: 1.5-4 hours postdose
Reported as:
Mean · mcg/L
Anti-FXa at Day 1 (1.5-4 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Anti-FXa at Day 1 (1.5-4 Hours Postdose)74.06 ± 32.4104.57 ± 55.5
PrimaryAnti-FXa at Day 4 (6-8 Hours Postdose)

Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Day 4: 6-8 hours postdose
Reported as:
Mean · mcg/L
Anti-FXa at Day 4 (6-8 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Anti-FXa at Day 4 (6-8 Hours Postdose)74.21 ± 60.6—
PrimaryAnti-FXa at Month 3 (Up to 3 Hours Predose)

Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: Up to 3 hours predose
Reported as:
Mean · mcg/L
Anti-FXa at Month 3 (Up to 3 Hours Predose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Anti-FXa at Month 3 (Up to 3 Hours Predose)60.51 ± 29.453.41 ± 15.0
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Time frame:
Up to 12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsRivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)91.785.985.3
PrimaryAnti-FXa at Month 3 (0.5-1.5 Hours Postdose)

Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 0.5-1.5 hours postdose
Reported as:
Mean · mcg/L
Anti-FXa at Month 3 (0.5-1.5 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Anti-FXa at Month 3 (0.5-1.5 Hours Postdose)—110.90 ± 75.8
PrimaryAnti-FXa at Month 3 (2.5-4 Hours Postdose)

Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.

Time frame:
Month 3: 2.5-4 hours postdose
Reported as:
Mean · mcg/L
Anti-FXa at Month 3 (2.5-4 Hours Postdose)
mcg/LRivaroxaban (Part A)Rivaroxaban (Part B)
Anti-FXa at Month 3 (2.5-4 Hours Postdose)—93.48 ± 50.3

Adverse events

Collected over Up to 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban (Part A)0/12 (0%)6/12 (50%)11/12 (91.7%)
Rivaroxaban (Part B)0/64 (0%)19/64 (29.7%)48/64 (75%)
Aspirin (Part B)0/34 (0%)8/34 (23.5%)26/34 (76.5%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventRivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/129/642/34
PyrexiaGeneral disorders1/120/640/34
BronchitisInfections and infestations1/120/640/34
LaryngitisInfections and infestations1/121/640/34
PneumoniaInfections and infestations1/121/641/34
Viral InfectionInfections and infestations1/120/640/34
Swelling FaceGeneral disorders0/120/641/34
InfluenzaInfections and infestations0/121/641/34
Viral Upper Respiratory Tract InfectionInfections and infestations0/120/641/34
Wound AbscessInfections and infestations0/120/641/34
Most frequent other events
Showing 10 of 50
Most frequent other events
EventRivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)
VomitingGastrointestinal disorders3/129/643/34
PyrexiaGeneral disorders0/1216/647/34
Viral Upper Respiratory Tract InfectionInfections and infestations3/120/641/34
NasopharyngitisInfections and infestations1/1214/646/34
CoughRespiratory, thoracic and mediastinal disorders0/1212/644/34
DiarrhoeaGastrointestinal disorders2/123/642/34
BronchitisInfections and infestations2/123/640/34
Upper Respiratory Tract InfectionInfections and infestations2/129/645/34
Viral InfectionInfections and infestations2/122/641/34
Dermatitis DiaperSkin and subcutaneous tissue disorders2/120/640/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)Total
Mean2.5 ± 0.674.1 ± 1.744.2 ± 1.83.9 ± 1.74
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)Total
Female5301146
Male7362366
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)Total
Hispanic or Latino1221134
Not Hispanic or Latino11421972
Unknown or Not Reported0246
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)Total
American Indian or Alaska Native0000
Asian014721
Black or African American38112
Native Hawaiian or Other Pacific Islander0000
White8402068
More than one race0000
Unknown or Not Reported0235
Other1236
Region of Enrollment
Region of Enrollment(Participants)Rivaroxaban (Part A)Rivaroxaban (Part B)Aspirin (Part B)Total
ARGENTINA0516
BELGIUM0549
BRAZIL071017
CANADA0336
JAPAN0819
MALAYSIA05510
MEXICO0628
NETHERLANDS0101
SPAIN5106
UNITED STATES725840
08

Study locations

42 sites
  • Los Angeles, California, United States
  • Gainesville, Florida, United States
  • Oak Lawn, Illinois, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Omaha, Nebraska, United States
  • Durham, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Milwaukee, Wisconsin, United States
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Brussel, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Curitiba, Brazil
  • Porto Alegre, Brazil
  • Sao Paulo, Brazil
  • Vancouver, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Fukuoka, Japan
  • Kitakyushu-shi, Japan
  • Setagaya Ku, Japan
  • Shizuoka-shi, Japan
  • Kuala Lumpur, Malaysia
  • Mexico, Mexico
  • Leiden, Netherlands
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
  • A Coruña, Spain
  • Barcelona, Spain
  • Bilbao, Spain
  • Madrid, Spain
  • Valencia, Spain
09

References and documents

Publications

  • McCrindle BW, Michelson AD, Van Bergen AH, Suzana Horowitz E, Pablo Sandoval J, Justino H, Harris KC, Jefferies JL, Miriam Pina L, Peluso C, Nessel K, Lu W, Li JS; UNIVERSE Study Investigators *. Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. J Am Heart Assoc. 2021 Nov 16;10(22):e021765. doi: 10.1161/JAHA.120.021765. Epub 2021 Sep 24. PubMed 34558312 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2020, 44 months.

Results were first posted in Mar 2022, 1 year 8 months after primary completion. A results delay was requested in Jul 2021.

Of 27 phase 3 interventional studies under Thrombosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 57. This study's 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2016
First posted
Jul 27, 2016
StartActual
Nov 16, 2016
Primary completionActual
Jul 16, 2020
CompletionActual
Jul 16, 2020
Results delay requested
Jul 13, 2021
Results first posted
Mar 28, 2022
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02846532
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jul 27, 2016
Start date
Nov 16, 2016
Primary completion
Jul 16, 2020
Completion
Jul 16, 2020
Results posted
Mar 28, 2022
Last update
Mar 30, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rivaroxaban · Aspirin

Start the discussion